LB Pharmaceuticals Inc.

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead program, LB-102, is an oral small-molecule candidate being advanced for acute schizophrenia and studied across additional psychiatric indications, including bipolar I depression and major depressive disorder. The company’s work centers on central nervous system medicines designed to address unmet needs in severe mental health disorders, with an emphasis on improving treatment options through differentiated pharmacology. LB Pharmaceuticals Inc. operates as a specialized drug developer within the healthcare sector and focuses on moving its pipeline through clinical development toward potential commercialization.

Sector

Healthcare

Industry

Biotechnology

CEO

Ms. Heather D. Turner Esq., J.D.

Employees

49

Headquarters

New York, NY, United States

Website

lbpharma.us